The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor – an alternative gene therapy

Celec, Peter; Gardlík, Roman; Pálffy, Roland; Hodosy, Július; Stuchlı́k, Stanislav; Drahovská, Hana; Stuchlíková, Martina; Minárik, Gabriel; Lukács, Ján; Jurkovičová, Ingrid; Hulín, I; Turňa, Ján; Jakubovský, J; Kopáni, Martin; Danišovič, Ľuboš; Jandzík, Dávid; Kúdela, Matúš; Yonemitsu, Yoshikazu

doi:10.1016/j.mehy.2004.07.039

Cited by 16 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor hypoxia and even bacterial chemotaxis towards chemo-attractant compounds in necrotic regions can be suggested as a contributing factors for tumor targeting [68]. In alternative gene therapy (AGT), bacteria produce a therapeutic protein in cells "in situ" or persist in intercellular spaces within the tumor environment which permits using of noninvasive strains [69,70]. After firstly reported Clostridium spp., tumor-specific replication has been demonstrated for Bifidobacterium spp, Salmonella spp, Escherichia coli, Vibrio cholerae and Listeria monocytogenes.…”

Section: Bacteria As Delivery Systems In Inflamation Tumor Preventiomentioning

confidence: 99%

Modification of microflora imbalance: future directions for prevention and treatment of colorectal cancer?

Ciernikova¹,

Mego²,

Hainova³

et al. 2015

neo

View full text Add to dashboard Cite

Increasing incidence and mortality of colorectal cancer brings the necessity to uncover new possibilities in the prevention, diagnosis and treatment. The microbiome as the collective genetic material of the microflora, overexceed the number of genes in the human genome and is unique for each individual. Due to the benefits providing for the host and mainly for immediate interaction with the host immune system, a gastrointestinal microflora can be considered "cardinal microbiome". Host-microbial relations includes symbiotic, pathogenic and competitive interactions. Causal role of gastrointestinal microflora in colorectal carcinogenesis is still not well determined. This minireview is focused on current evidence in understanding the role of bacteria in colorectal carcinogenesis, the impact of bacterial dysbiosis on tumor formation, and ability of probiotics and bacterial vectors to modulate the gastrointestinal microflora as prevention and therapy tool in colorectal cancer.

show abstract

Section: Bacteria As Delivery Systems In Inflamation Tumor Preventiomentioning

confidence: 99%

Modification of microflora imbalance: future directions for prevention and treatment of colorectal cancer?

Ciernikova¹,

Mego²,

Hainova³

et al. 2015

neo

View full text Add to dashboard Cite

show abstract

“…Despite recent progress, only a few recent studies on bacterial delivery systems have specifically focused on antiangiogenic gene therapy. Although effects on the vasculature were observed in most of these studies, the resulting changes seemed to be a consequence mainly of bacteria-mediated therapy [54]. But for bacteria mediated anti-angiogenesis gene therapy, it is a reasonable approach given that solid tumors are often characterized by increased vascularization [43].…”

Section: Bacterial Vectorsmentioning

confidence: 99%

Emerging biotechnological strategies for non-viral antiangiogenic gene therapy

Liu

Zhang

2012

Angiogenesis

View full text Add to dashboard Cite

Angiogenesis has emerged as a promising target of cancer treatment. With the development of biotechnology, major progress has been made in the exploring effective therapies on targeting tumor angiogenesis over the last 20 years. Gene therapy has attracted considerable interest by virtue of the capabilities of expressing sustained levels of therapeutic agents within cells of the patients. However, the major challenge of gene therapy is the efficient delivery of therapeutic gene to the target site. Compared with viral strategies, non-viral strategies were more acceptable by their widely recognized security and lower side effects. This paper reviews the basic biology of angiogenesis, the potential advantages of antiangiogenic gene therapy, the therapeutic genetic drugs developed through biotechnology, as well as the biotechnological strategies that enhancing non-viral gene therapy targeting to tumor angiogenesis in a more controlled manner, with great respect to RNA interference, ligand-directed vascular targeting strategies, vascular endothelial growth factor pathway and tumor associated macrophages targeting. In conclusion, antiangiogenic gene therapy holds great promise in advancing cancer therapy. Developing better non-viral biotechnological platforms will benefit antiangiogenic targeted cancer gene therapeutic methods, support their evaluation in human clinical trials and realize the actual utilization in the near future.

show abstract

“…13 Bacteria are not used for the gene transfer but should persist in the target tissues. Persisting bacteria produce the therapeutical polypeptide in situ, thus, this technique resembles bacterial protein delivery ( Figure 2; Table 3).…”

Section: What Is Bactofection?mentioning

confidence: 99%

Bacteria in gene therapy: bactofection versus alternative gene therapy

et al. 2005

View full text Add to dashboard Cite

Recent advances in gene therapy can be attributed to improvements of gene delivery vectors. New viral and nonviral transport vehicles that considerably increase the efficiency of transfection have been prepared. However, these vectors still have many disadvantages that are difficult to overcome, thus, a new approach is needed. The approach of bacterial delivery could in the future be important for gene therapy applications. In this article we try to summarize the most important modifications that are used for the preparation of applied strains, difficulties that are related with bacterial gene delivery and the current use of bactofection in animal experiments and clinical trials. Important differences to the alternative gene therapy (AGT) are discussed. AGT resembles bacteria-mediated protein delivery, as the therapeutical proteins are produced not by host cells but by the bacteria in situ and the expression can be regulated exogenously. Although the procedure of bacterial gene delivery is far from being definitely solved, bactofection remains a promising technique for transfection in human gene therapy.

show abstract

The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor – an alternative gene therapy

Cited by 16 publications

References 33 publications

Modification of microflora imbalance: future directions for prevention and treatment of colorectal cancer?

Modification of microflora imbalance: future directions for prevention and treatment of colorectal cancer?

Emerging biotechnological strategies for non-viral antiangiogenic gene therapy

Bacteria in gene therapy: bactofection versus alternative gene therapy

Contact Info

Product

Resources

About